Screener
Viking Therapeutics VKTX Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Revenues | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Loss from operations | (164,125) | (55,469) |
| Other income (expense): | ||
| Amortization of financing costs | — | (24) |
| Interest income, net | 5,800 | 9,864 |
| Total other income, net | 5,800 | 9,840 |
| Net loss | (158,325) | (45,629) |
| Other comprehensive loss, net of tax: | ||
| Unrealized (loss) gain on securities | (1,250) | 563 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's interest expense?
- Viking Therapeutics (VKTX) reported interest expense of $5.8M in Q1 2026.
- How has Viking Therapeutics's interest expense changed year-over-year?
- Viking Therapeutics's interest expense decreased by 41.2% year-over-year, from $9.86M to $5.8M.
- What is the long-term trend for Viking Therapeutics's interest expense?
- Over 4 years (2021 to 2025), Viking Therapeutics's interest expense has grown at a 163.0% compound annual growth rate (CAGR), from $704K to $33.7M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Viking Therapeutics's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude